SUVEN PHARMACEUTICALS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 643.1 INR | +1.00% |
|
-1.09% | -11.44% |
| Mar. 27 | Suven Pharmaceuticals Limited Announces Shifting of Registered Office | CI |
| Mar. 05 | Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call |
| Sales 2023 | 13.4B 161M | Sales 2024 * | 10.9B 131M | Capitalization | 163B 1.96B |
|---|---|---|---|---|---|
| Net income 2023 | 4.11B 49.34M | Net income 2024 * | 3.34B 40.09M | EV / Sales 2023 | 8.97 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 15 x |
| P/E ratio 2023 |
29.2
x | P/E ratio 2024 * |
48.8
x | Employees | 1,193 |
| Yield 2023 * |
0.37% | Yield 2024 * |
0.27% | Free-Float | 37.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Suven Pharmaceuticals Limited
| 1 day | +1.00% | ||
| 1 week | -1.09% | ||
| Current month | -4.95% | ||
| 1 month | +0.12% | ||
| 3 months | -5.77% | ||
| 6 months | +11.90% | ||
| Current year | -11.44% |
1 week
626.90
649.55
1 month
608.35691.65
Current year
586.10767.00
1 year
427.05767.00
3 years
375.00767.00
5 years
87.05767.00
10 years
87.05767.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sudhir Singh
CEO | Chief Executive Officer | - | 23-09-28 |
Himanshu Agarwal
DFI | Director of Finance/CFO | 30 | Dec. 31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 23-09-28 | |
Shweta Jalan
BRD | Director/Board Member | 48 | Nov. 08 |
| Director/Board Member | 62 | Nov. 08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 643.1 | +1.00% | 2 068 |
| 24-04-24 | 636.8 | -1.10% | 1,651 |
| 24-04-23 | 643.8 | +0.98% | 5,883 |
| 24-04-22 | 637.6 | -0.73% | 6,444 |
| 24-04-19 | 642.3 | -1.22% | 5,416 |
Delayed Quote Bombay S.E., April 25, 2024 at 02:44 am EDT
More quotes
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Companyâs wholly owned subsidiary is Suven Pharma Inc.
Sector
Pharmaceuticals
Calendar
2024-06-19
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
641.5
INR
Average target price
685.5
INR
Spread / Average Target
+6.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- SUVENPHAR Stock
- SUVENPHAR Stock
